TUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

The new vaccine (mNexspike [COVID-19 Vaccine, mRNA]) represents a significant step forward in the development of next-generation coronavirus vaccines, the Associated Press reported . The innovative design of mNexspike allows for a much lower dose, about one-fifth of the dosage used in the current vaccine (Spikevax), a reduction achieved by refining the vaccine's target to elicit a more focused immune response.

The vaccine is not a replacement for the current Moderna COVID-19 vaccine. The lower-dose vaccine is intended to be a second option.

mNexspike is approved for us

See Full Page